Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Background & Objective: Although data on the effects of liraglutide and semaglutide in patients with diabetes have been reviewed, their therapeutic outcomes in obese/overweight individuals without diabetes have not been summarized. We conducted a systematic review to evaluate their effects on the latter population. Methods: We searched the PubMed, EMBASE, Cochrane, CNKI, and Wanfang databases. Studies regarding obese/overweight adults without diabetes treated with liraglutide/semaglutide compared with other active agents or placebos were accessed. The primary outcomes were the proportions of adults with at least 5% and 10% weight reduction. The secondary outcomes included metabolic indicators and adverse events. Results: Eighteen studies with 10,938 obese/overweight adults without diabetes were included. When stratified by the categories of at least 5% and 10% weight loss, the pooled data showed medians 27.7% and 10.3% of control groups versus 65.3% and 30.7% of liraglutide 3 mg once daily, respectively; whereas medians 47.6% and 20.4% of control groups vs 86.6% and 75.3% of semaglutide 2.4 mg once weekly were found in the two categories, respectively. Both agents either improved or had no impact on lipid or glycemia. Liraglutide or semaglutide therapy had discontinuation rates of 2.4%–11.4% which overlapped with 0.7%–8.6% in control groups. The frequency of adverse events was comparable between the treatment groups and the control groups (66.5%–95.8% vs 46.9%–96.1%), which were mild to moderate graded by studies. Conclusion: Liraglutide and semaglutide therapy led to a clinically relevant (⩾5%) weight loss of 48.2%–88.7% among obese/overweight adults without diabetes. Both liraglutide and semaglutide are associated with weight loss and are well-tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
‘Small Changes' to Diet and Physical Activity Behaviors for Weight Management
Hills, A. P., Byrne, N. M., Lindstrom, R., & Hill, J. O. (2013) · Obesity Facts · doi:10.1159/000345030 · Cited by 9,493
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Haslam, D. W., & James, W. P. T. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67483-1 · Cited by 3,757
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821 · cited 2×
“Eligibility criteria We defined studies as eligible for inclusion in this analysis if they met the following criteria: (1) Obese/overweight adults who use liraglutide or semaglutide; (2) RCTs, observational studies; (3) reporting clinical events data of efficacy and safety; and (4) published before 2021/8/1, English o…”
BackgroundMethodA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
DONNELLY, J. E., BLAIR, S. N., JAKICIC, J. M., MANORE, M. M., RANKIN, J. W., & SMITH, B. K. (2009) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181949333 · Cited by 2,658
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Obesity Phenotypes, Diabetes, and Cardiovascular Diseases
Piché, M.-E., Tchernof, A., & Després, J.-P. (2020) · Circulation Research · doi:10.1161/circresaha.120.316101 · Cited by 1,986
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Obesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114 · cited 2×
“…vs 44.0 (20/46) 46.0 (21/45) vs 26.0 (12/46) 28.0 (13/45) vs 12.0 (6/46) Astrup et al.20 73.0 (55/75) vs 28.0 (21/74) 37.0 (28/75) vs 10.0 (16/74) NR Wadden et al.21 50.5 (80/159) vs 1.8 (3/146) NR NR Ferrari et al.27 68.3 (49/72) vs NR 20.0 (14/72) vs NR 10.0 (7/72) vs NR Gorgojo-Martínez et…”
InfluentialNeeland, I. J., Poirier, P., & Després, J.-P. (2018) · Circulation · doi:10.1161/circulationaha.117.029617 · Cited by 881 · cited 2×
“Eligibility criteria We defined studies as eligible for inclusion in this analysis if they met the following criteria: (1) Obese/overweight adults who use liraglutide or semaglutide; (2) RCTs, observational studies; (3) reporting clinical events data of efficacy and safety; and (4) published before 2021/8/1, English o…”
BackgroundMethodKhera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016) · JAMA · doi:10.1001/jama.2016.7602 · Cited by 865
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814
Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Treatment of Obesity: Weight Loss and Bariatric Surgery
Wolfe, B. M., Kvach, E., & Eckel, R. H. (2016) · Circulation Research · doi:10.1161/circresaha.116.307591 · Cited by 648
Gadde (2018) · doi:10.1016/j.jacc.2017.11.011 · Cited by 626
on behalf of the SCALE study group, Blackman, A., Foster, G. D., Zammit, G., Rosenberg, R., Aronne, L., Wadden, T., Claudius, B., Jensen, C. B., & Mignot, E. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.52 · Cited by 583
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028198 · Cited by 536
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
Screening for Obesity in Adults: Recommendations and Rationale
U.S. Preventive Services Task Force* (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-11-200312020-00012 · Cited by 347
Enebo, L. B., Berthelsen, K. K., Kankam, M., Lund, M. T., Rubino, D. M., Satylganova, A., & Lau, D. C. W. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00845-x · Cited by 316
Dietary interventions for obesity: clinical and mechanistic findings.
Chao, A. M., Quigley, K. M., & Wadden, T. A. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140065 · Cited by 257
Yamada, Y., Katagiri, H., Hamamoto, Y., Deenadayalan, S., Navarria, A., Nishijima, K., Seino, Y., Fukushima, Y., Hamamoto, Y., Hisatomi, A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30075-9 · Cited by 228
Semaglutide for the treatment of obesity
Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.008 · Cited by 227
Complications of bariatric surgery: Presentation and emergency management
Kassir, R., Debs, T., Blanc, P., Gugenheim, J., Ben Amor, I., Boutet, C., & Tiffet, O. (2016) · International Journal of Surgery · doi:10.1016/j.ijsu.2016.01.067 · Cited by 220
Drug therapy in obesity: a review of current and emerging treatments
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00816-y · Cited by 195
Obesity: Current and potential pharmacotherapeutics and targets
Narayanaswami, V., & Dwoskin, L. P. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.015 · Cited by 186
Tsapas, A., Karagiannis, T., Kakotrichi, P., Avgerinos, I., Mantsiou, C., Tousinas, G., Manolopoulos, A., Liakos, A., Malandris, K., Matthews, D. R., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14451 · Cited by 179
Semaglutide as a promising antiobesity drug
Christou, G. A., Katsiki, N., Blundell, J., Fruhbeck, G., & Kiortsis, D. N. (2019) · Obesity Reviews · doi:10.1111/obr.12839 · Cited by 159
Wadden, T. A., Walsh, O. A., Berkowitz, R. I., Chao, A. M., Alamuddin, N., Gruber, K., Leonard, S., Mugler, K., Bakizada, Z., & Tronieri, J. S. (2019) · Obesity · doi:10.1002/oby.22359 · Cited by 116
Best Practices in the Management of Overweight and Obesity
Tchang, B. G., Saunders, K. H., & Igel, L. I. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.08.018 · Cited by 91
Gorgojo‐Martínez, J. J., Basagoiti‐Carreño, B., Sanz‐Velasco, A., Serrano‐Moreno, C., & Almodóvar‐Ruiz, F. (2019) · International Journal of Clinical Practice · doi:10.1111/ijcp.13399 · Cited by 82
Ahmad, N. N., Robinson, S., Kennedy‐Martin, T., Poon, J. L., & Kan, H. (2021) · Obesity Reviews · doi:10.1111/obr.13326 · Cited by 69
Current Drug Targets in Obesity Pharmacotherapy – A Review
Bhat, S. P., & Sharma, A. (2017) · Current Drug Targets · doi:10.2174/1389450118666170227153940 · Cited by 60 · cited 1×
“We excluded these publications: (1) age less than 18 years old; (2) with diabetes; (3) animal studies; (4) case reports, case series, or the sample size was too small (N < 10); and (5) unpublished studies.”
BackgroundLiraglutide in the management of type 2 diabetes
Wajcberg, E., & Amarah, A. R. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s10180 · Cited by 54
Ariel, D., Kim, S. H., Abbasi, F., Lamendola, C. A., Liu, A., & Reaven, G. M. (2014) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.06.010 · Cited by 38
Gastrointestinal traits: individualizing therapy for obesity with drugs and devices
Camilleri, M., & Acosta, A. (2016) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2015.08.007 · Cited by 34
Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis
Alsugair, H. A., Alshugair, I. F., Alharbi, T., Rsheed, A. M. B., Tourkmani, A. M., & Almadani, W. H. (2021) · Healthcare · doi:10.3390/healthcare9091125 · Cited by 34
Weight loss effect of liraglutide in real-life: the experience of a single Italian obesity center
Ferrari, F., Fierabracci, P., Salvetti, G., Jaccheri, R., Vitti, J., Scartabelli, G., Meola, A., Magno, S., Ceccarini, G., & Santini, F. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01334-1 · Cited by 29
Instrumentalization of Eating Improves Weight Loss Maintenance in Obesity
Christensen, B. J., Iepsen, E. W., Lundgren, J., Holm, L., Madsbad, S., Holst, J. J., & Torekov, S. S. (2017) · Obesity Facts · doi:10.1159/000481138 · Cited by 28
Dose response of subcutaneous GLP‐1 infusion in patients with type 2 diabetes
Torekov, S. S., Kipnes, M. S., Harley, R. E., Holst, J. J., & Ehlers, M. R. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01388.x · Cited by 25
Chou, C., & Chuang, S. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13314 · Cited by 25
Sauer, N., Reining, F., Schulze zur Wiesch, C., Burkhardt, T., & Aberle, J. (2014) · Hormone and Metabolic Research · doi:10.1055/s-0034-1387793 · Cited by 16
Gillani, S. M. R., & Singh, B. M. (2015) · The British Journal of Diabetes · doi:10.15277/bjdvd.2015.011 · Cited by 8
Research works printed but not linked: 2
- Zhou JL, 2018, J Pract Diabetol, 2018, 13
- Sauer N, 2015, Horm Metab Res, 47, 560
Cited by
Sherwin, M., Hamburger, J., Katz, D., & DeMaria, S. (2023) · Canadian Journal of Anesthesia/Journal canadien d'anesthésie · doi:10.1007/s12630-023-02549-5 · Cited by 132
“Indeed, use of GLP1RAs in patients with no obesity is an increasingly accepted and studied practice.(30)”
BackgroundGlucagon‐like peptide agonists: A prospective review
Mariam, Z., & Niazi, S. K. (2023) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.462 · Cited by 130
Moll, H., Frey, E., Gerber, P., Geidl, B., Kaufmann, M., Braun, J., Beuschlein, F., Puhan, M. A., & Yebyo, H. G. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102661 · Cited by 73
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
Lawrence, E. C. N., Guo, M., Schwartz, T. D., Wu, J. J., Lu, J., Nikonov, S. S., Sterling, J. K., & Cui, Q. N. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1156829 · Cited by 45
Metadata
- Authors
- Deng, Y., Park, A., Zhu, L., Xie, W., & Pan, C. Q.
- Affiliations
- Capital Medical University (CN)
- Northern Valley Regional High School at Old Tappan, Old Tappan, NJ, USA
- Corresponding author
- Xie, Wen
- Venue
- Therapeutic Advances in Chronic Disease
- Publisher
- SAGE Publications
- Published
- 2022-01
- Volume
- 13
- Pages
- 20406223221108064-20406223221108064
- ISSN
- 2040-6223 (ISSN-L)
- 2040-6231
- PMC
- PMC9260566
- OpenAlex
- W4285035640
- Semantic Scholar
- 34ae896c105249b614dcc187978f767606d4d277
- Cited by
- 51
- References
- 54
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 14 · 2023: 13
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Therapeutic Advances in Chronic Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation Youth Fund Project (81600454)
- Clinical Medicine Development Project of Beijing Municipal Administration of Hospitals (ZYLX201828)
- National Natural Science Foundation of China (81770577)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- semaglutide, liraglutide, obesity, overweight, weight loss, GLP-1 receptor agonists, non-diabetic adults, adverse events, treatment discontinuation, glycemic control, lipid profile
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.